CA2313659A1 - B complex vitamin compositions that protect against cellular damage caused by ultraviolet light - Google Patents
B complex vitamin compositions that protect against cellular damage caused by ultraviolet light Download PDFInfo
- Publication number
- CA2313659A1 CA2313659A1 CA002313659A CA2313659A CA2313659A1 CA 2313659 A1 CA2313659 A1 CA 2313659A1 CA 002313659 A CA002313659 A CA 002313659A CA 2313659 A CA2313659 A CA 2313659A CA 2313659 A1 CA2313659 A1 CA 2313659A1
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- composition
- cells
- light
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 229940088594 vitamin Drugs 0.000 title claims abstract description 22
- 229930003231 vitamin Natural products 0.000 title claims abstract description 22
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 22
- 239000011782 vitamin Substances 0.000 title claims abstract description 22
- 150000003722 vitamin derivatives Chemical class 0.000 title abstract description 11
- 230000005779 cell damage Effects 0.000 title description 3
- 235000019152 folic acid Nutrition 0.000 claims abstract description 75
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 52
- 239000011724 folic acid Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 33
- 229940014144 folate Drugs 0.000 claims abstract description 25
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 24
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 24
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 24
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 15
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 15
- 239000011570 nicotinamide Substances 0.000 claims abstract description 15
- 206010051246 Photodermatosis Diseases 0.000 claims abstract description 8
- 230000000254 damaging effect Effects 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 3
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002502 liposome Substances 0.000 claims description 4
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims description 3
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 150000006636 nicotinic acid Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 abstract description 34
- 239000003795 chemical substances by application Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 13
- 229960000304 folic acid Drugs 0.000 abstract description 13
- 230000000699 topical effect Effects 0.000 abstract description 13
- 231100000024 genotoxic Toxicity 0.000 abstract description 7
- 230000001738 genotoxic effect Effects 0.000 abstract description 7
- 230000008845 photoaging Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 231100000219 mutagenic Toxicity 0.000 abstract description 5
- 230000003505 mutagenic effect Effects 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- 230000000711 cancerogenic effect Effects 0.000 abstract description 4
- 231100000315 carcinogenic Toxicity 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 3
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 3
- 239000007921 spray Substances 0.000 abstract description 3
- 239000004098 Tetracycline Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- 235000019364 tetracycline Nutrition 0.000 abstract description 2
- 150000003522 tetracyclines Chemical class 0.000 abstract description 2
- 230000003711 photoprotective effect Effects 0.000 abstract 3
- 229930003451 Vitamin B1 Natural products 0.000 abstract 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 abstract 2
- 229960003495 thiamine Drugs 0.000 abstract 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 2
- 235000010374 vitamin B1 Nutrition 0.000 abstract 2
- 239000011691 vitamin B1 Substances 0.000 abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 229930003761 Vitamin B9 Natural products 0.000 abstract 1
- 208000009621 actinic keratosis Diseases 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 235000000639 cyanocobalamin Nutrition 0.000 abstract 1
- 239000011666 cyanocobalamin Substances 0.000 abstract 1
- 229960002104 cyanocobalamin Drugs 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 230000002165 photosensitisation Effects 0.000 abstract 1
- 208000017983 photosensitivity disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940040944 tetracyclines Drugs 0.000 abstract 1
- 235000019159 vitamin B9 Nutrition 0.000 abstract 1
- 239000011727 vitamin B9 Substances 0.000 abstract 1
- 150000002224 folic acids Chemical class 0.000 description 39
- 210000003491 skin Anatomy 0.000 description 24
- 239000000516 sunscreening agent Substances 0.000 description 23
- 230000000475 sunscreen effect Effects 0.000 description 20
- 208000000453 Skin Neoplasms Diseases 0.000 description 17
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 16
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 12
- 201000000849 skin cancer Diseases 0.000 description 12
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 235000008191 folinic acid Nutrition 0.000 description 8
- 239000011672 folinic acid Substances 0.000 description 8
- 229960001691 leucovorin Drugs 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000036561 sun exposure Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- UDOGNMDURIJYQC-UHFFFAOYSA-N 2-amino-6-methyl-1h-pteridin-4-one Chemical compound N1C(N)=NC(=O)C2=NC(C)=CN=C21 UDOGNMDURIJYQC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 150000001607 bioavailable molecules Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 239000011578 levomefolic acid Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- -1 methenyl Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003230 pyrimidines Chemical group 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000005460 tetrahydrofolate Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 description 1
- MEANFMOQMXYMCT-OLZOCXBDSA-N 5,10-methenyltetrahydrofolic acid Chemical compound C([C@H]1CNC2=C([N+]1=C1)C(=O)N=C(N2)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 MEANFMOQMXYMCT-OLZOCXBDSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010049422 Precancerous skin lesion Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- WYWZRNAHINYAEF-AWEZNQCLSA-N [(2s)-2-ethylhexyl] 4-(dimethylamino)benzoate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-AWEZNQCLSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940024874 benzophenone Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940042566 combination folic acid Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229960002638 padimate o Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical group N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Abstract
The present invention relates generally to the use of vitamin B12 (cobalamin or cyanocobalamin) alone or in combination with other photoprotective agents, including specifically other vitamins such as vitamin (folic acid or folate) and vitamin B1 (niacin or niacinamide), or any chemical derivative of these vitamins and their salts, as a filter to protect cells against the damaging effects of ultraviolet (UV) light. The invention is, in one aspect, a method of reducing the rate of UV damage to cells exposed to a UV light source, by treating the cells with the vitamin composition, either alone or in combination with other photoprotective agents. Other aspects of the invention are compositions comprising effective amounts of vitamin B12 alone or in combination with other photoprotective agents including vitamin B9 and vitamin B1 and a pharmaceutically-acceptable carrier, that are useful in protecting cells, particularly skin cells, against the burning, genotoxic (mutagenic and carcinogenic), immunosuppressive and photoaging effects of UV light, especially sunlight. The invention has application as a UV light filter in oral preparations, topical creams, lotions, sprays, wipes and cosmetics. The invention also has application as a medicinal treatment for dermatological conditions caused by exposure to sunlight,(eg actinic keratoses, photodermatitis, lupus erythematosus) and the photosensitizing effects of a variety of drugs used commonly in clinical practice (eg antihistamines, ACE inhibitors, and tetracyclines).
Description
x n.
B COMPLEX VITAMIN COMPOSITIONS THAT PROTECT AGAINST
CELLULAR DAMAGE CAUSED BY ULTRAVIOLET LIGHT
FIELD OF THE INVENTION
The invention relates generally to sunscreens and sunfilters, and to methods and compositions for protecting cells against the damaging effects of sunlight and artificial sources of UV light such as lamps and arc welding equipment.. In particular, the invention is directed to the use of vitamin B12, alone or in combination with folate (used here to refer to the family of folic acid derivatives found commonly in nature), and niacin (specifically niacinamide) in methods and compositions for protecting cells and organisms including humans against the burning, genotoxic, immunosuppressive and photoaging effects of UV
light.
BACKGROUND OF THE INVENTION
Over the past several decades, the worldwide incidence of skin cancer has been increasing at an alarming rate. The reason for this dramatic increase in skin cancers and the human suffering associated with these disorders is not entirely clear, but many experts believe that it is due, at least in part, to depletion of the earth's protective ozone layer. It is likely that the widespread use of sunscreens that protect against some but not all of the sun's harmful UV
radiation (UVB but not UVA) also has played a role. According to the National Cancer Institute (NCI), there will be over one million new cases of skin cancer reported in the United States this year. This nears the total of all other cancers combined. NCI also reported that if present trends continue 40-50% of fair skinned Americans are expected to develop at least one type of skin cancer by age sixty-five. These numbers are alarming, but in regions of the world closer to the equator, the rates of skin cancer are even higher.
In some regions of Australia for example, the probability of non-indigenous people (most of whom are of European descent) developing skin cancer at some point during their lifetime approaches 100%. Skin cancers are now the main cause of death in Australia of all persons between the ages of 25 and 40. Worldwide, skin cancer is expected to become the leading cause of death due to malignant disease in the next decade.
How did this alarming situation come about? It is likely that the worldwide pandemic of skin cancers is due to a number of causal factors. These include lifestyle choices (suntanning, increased outdoor leisure activities), an aging population (due to chronic sun exposure and decreased DNA repair capacity) dietary factors (folic acid is the most common nutritional deficiency in the world and other micro-nutrient deficiencies) and environmental factors (workplace hazards and depletion of the ozone layer). In addition to increased risk of skin cancer, exposure to sunlight has a variety of adverse effects on the human body including erythema (burning of the skin), photoaging (wrinkling) and suppression of the immune system. Recently it has also been suggested that sunlight exposure in women might also increase the risk of neural tube defects in _2_ the developing fetus (ref) and risk of developing endometriosis (a condition characterized by invasion of the inner lining (endometrium) tissue into the outer layers of the uterus.) For many years it was thought by most scientific investigators that these various effects were quite separate consequences of sunlight exposure.
However, recent evidence has suggested that many of the effects of solar light on the human body might be interrelated. For example, children who experience only a single episode of blistering sunburn in childhood (before the age of 18) double their risk of developing skin cancer later in life. Tanning of the skin, long thought to be an important component of a healthy lifestyle is now considered by most experts to be quite the opposite and should be more properly considered as simply the unhealthy appearance of sundamaged skin. In addition, contrary to another widely held belief, it is now well documented that tanning confers no protection whatsoever against the most serious effect of chronic sun exposure, the increased risk of skin cancer.
The skin cancers induced by sunlight can be broadly categorized into two types: melanomas and non-melanomas (basal-cell and squamous). It was generally accepted for some time that exposure to UVB (the burning rays of the sun with the wavelengths ranging from 280 to 315 nm) was responsible for the induction of melanomas, the most serious form of skin cancer and the tumor type responsible for most deaths. This was held to be especially true in those individuals who had at least one episode of severe sunburn early in childhood.
It seems likely from more recent studies, (especially an elegant series of experiments by Dr Richard Setlow reported recently to the American Academy of Dermatology that this is simply not the case. Based on spectral and mutational fingerprint analysis (each type of UV light causes a characteristic mutational pattern in target genes) Dr Setlow suggests that melanomas are due mainly to chronic exposure to UVA, wrongly considered by many people to be the harmless tanning rays of the sun, UVA has wavelengths between 320 and 400 nm. UVA has less energy than UVB but is more penetrating and passes through window glass and into deeper layers of the skin more easily.
Recent experimental evidence suggests UVB induces mainly non-melanoma skin cancers.
There are several implications of this new understanding of the carcinogenic potential of UVA and UVB. First, UVA light passes easily through the atmosphere and is not absorbed by the ozone layer. It is the main type of solar UV irradiation (about 95%) that reaches the surface of the earth. In the past, it was generally believed that UVA had only beneficial effects to humans such as stimulation of vitamin D formation and tanning. However, this is clearly not the case. Wavelengths in the UVA range induce melanomas. Second depletion of the ozone layer which permits passage of more UVB light cannot be the explanation for the dramatic increase in melanomas seen worldwide in recent years. More likely it is due to the widespread use of sunscreen products that slow burning of the skin by filtering UVB and give a false impression to the user that sundamage is not occurring. These individuals are not only at greater risk of melanoma formation but also increased risk of photoaging of the skin suppression of their immune system. Lastly, chronic exposure to UVA over the lifetime of an individual and not acute sunburn in childhood is now considered to be responsible for the majority of melanomas, the most serious form of skin cancer and the type causing most deaths (six out of seven deaths due to skin cancer in the United States are caused by melanomas). The general implication of these findings is that tanning is unhealthy whether done in sunlight or by exposure to artificial sources of UVA such as those used in salons. It is now recommended by the US FDA that people avoid tanning salons altogether and that sunscreen products should contain both UVA and UVB filters.
The mechanism of UV damage to skin is only partly understood. The harmful effects of UVA and UVB light on human skin are due primarily to direct cellular damage (see Princiales and Practice of Dermatology, 2nd Edition, Williams and Wilkins, Churchill/Livingston, N.Y.). Suppression of the immune system also occurs but by an indirect mechanism. The genotoxic potential of solar light resides mainly in the ability of UV to damage DNA (DNA absorbs maximally at 254nm). UV light causes the formation of various photoproducts in the strands of the DNA molecule. The major photoproducts caused by UV light are dimers (fusions) of adjacent pyrimidines (thymine or cytosine residues) in one of the two strands of the DNA molecule. Other minor products like 6,4 photoproducts also occur. But DNA is not the only target of UV light. UV also damages other cellular components such as collagen. This causes photoaging of the skin. But the main genotoxic (mutagenic and carcinogenic) effects of UV
light seems to reside in the ability of UV wavelengths to damage DNA. The cancer causing effects of UV light are can also reside in the ability of these wavelengths to impair the body's immunosurveillance system whose job it is to detect and destroy potentially malignant cells. In the absence of a properly functioning immunosurveillance system, skin cancers arising from cells harboring tumorigenic mutations caused by sunlight are more likely.
In the art numerous screening and ~Itering agents have been developed over many years, to protect skin against the deleterious affects of UV light.
These agents are applied directly to the skin of a subject, and are believed to prevent UV light from penetrating the epidermis by acting as "filters,"
thereby absorbing or otherwise dissipating the energy contained in photons of UV
light.
Previously it was widely accepted in the industry that agents called "sunblocks"
decreased UV-induced DNA damage, and in particular, pyrimidine dimer formation by UV opaque substances. In support of this view a recent clinical study indicated that "sunblocks" such as titanium oxide significantly reduced the incidence of pre-cancerous skin lesions in sunlight-exposed subjects. However, the term "sunblock" is no longer accepted by the US Food and Drug Agency (FDA). The FDA believes the term is misleading as no agent truly "blocks" all harmful UV rays and implies a greater degree of protection from the damaging effects of sunlight than is warranted.
Para-aminobenzoic acid (pABA), was one of the first sunfiltering agents to be identified in the art. It is now seldom used because of problems with contact dermatitis. Due to widespread use of pABA over many years about 10% of all users of sunscreen products have some degree of contact sensitivity to the compound. However, esters of pABA, particularly octyl, dimethyl, para-aminobenzoic acid, do not elicit these same skin reactions. Other commonly used sunfilters are compounds from the salicyclate, cinnamate, benzophenone, anthranilate, and dibenzoylmethane families of molecules. It is well known in the art to combine sunfiltering agents that absorb UV light in different portions of the spectrum. However, most of these agents are synthetic chemicals not found in commonly in nature and it is not known what effects longterm use of these compounds may have on the human body.
Sunscreen compositions exert their effects through filtering or absorbing UV light so that the damaging wavelengths do not penetrate the various layers of the skin. To be effective, sunscreens must be present on the skin as a continuous film, and must remain on the surface of the skin throughout the period of UV exposure. One of the problems with products currently in use is that despite numerous attempts to develop topical compositions that act as sunscreen carriers and remain on the surface of the skin (see U.S. Patent No.
5,087,445), sunscreens tend to rub off on towels and clothing, and wash off in perspiration, or during swimming, showering and bathing. Even if carriers are developed that remain on the surface of the skin for longer periods absorption of sunscreen (and cosmetic) additives into the skin remains a problem. This is due to the surprising fact that many sunfiltering agents used as sunscreen and cosmetic additives themselves cause DNA damage. Titanium dioxide for example a very common additive has long been considered to be safe and effective as a sunscreening agent. This may not be the case (see Salinaro et al., 1997, "Chemical oxidation and DNA damage catalysed by inorganic sunscreen ingredients" FEES Lett 418:87-90). Padimate-O, another common sunscreen additive in widespread use may also be genotoxic ( see P.J. McHugh and J.
Knowland, 1997, "Characterization of DNA damage inflicted by free radicals from a mutagenic sunscreen ingredient and its location using an in vitro genetic reversion assay" Photochem Photbiol 66:276-281.]
A recent research article (G.J. Cameron et al., 1997, "Systemic absorption of sunscreen after topical application" The Lancet 350: 863-864) has shown that the UVA sunscreen oxybenzone, a benzophenone derivative used commonly worldwide to make sunscreen products with high sun protection factors (SPF) is absorbed systemically and excreted in human urine soon after application to the skin. The repeated use of a sunscreen that is absorbed systemically could pose an especially high risk to human health if the sunscreen agent is chronically genotoxic. A recent and alarming finding is that at low concentration most if not all of the sunscreen agents currently in use are both mutagenic and tumorigenic (R C von Borstel, personal communication). The tumor incidence was very high in along the borders of applied sunscreen in experimental animals.
These findings have added a new urgency to the development of novel sunfiltering agents that are not only effective in reducing the harmful effects of UV light, but are also safe, even upon repeated usage and over a long period of time. Subsequent to experiments on the role of the vitamin folic acid in the repair of UV damage to DNA ( see Barclay et al exp med boil 1993) my collaborators and I discovered what we believe might be a natural sunfilter in the human body.
-8_ The compound is a folate which occurs naturally in the bloodstream and is also associated with hemoglobin in red blood cells.
SUMMARY OF THE INVENTION
The object of the invention is to provide a means of reducing the burning, genotoxic, immunosuppressive and photoaging effects of UV light by application of three common B vitamins to the skin The term "vitamin B12", "folate" and "niacinamide" as used herein, includes the parent compounds, their precursors (pro-vitamins), metabolites, derivatives, and their conjugates, all of which may be either naturally occurring or synthetic, as well as the salts of the compounds. Results of experiments with human volunteers described below have shown that the combination folic acid, vitamin B12 and niacinamide when taken in pill form prevented sunburning for many hours. It is assumed that topical application would be effective in a similar fashion.
Broadly speaking, the invention provides a method for reducing UV
damage to cells, comprising exposing the cells to an amount of at least one of vitamin B12 or folate but preferably the two vitamins in combination with niacinamide, in appropriate concentration, which is sufficient to reduce UV
damage to cells, specifically skin cells. In one embodiment, the invention is a method for reducing UV damage to the outer cell layers of a subject, comprising administering to the subject a formulation of vitamin B12, folate and niacinamide, in a suitable carrier, the amounts of each individual component sufficient to _g_ reduce UV damage to cells. In one preferred embodiment, the carrier is suitable for topical application, and the composition is applied to the skin of the subject.
In another preferred embodiment, the carrier is suitable for oral administration, and the composition is ingested by the subject. In another preferred embodiment, the three B vitamins, in suitable carriers, are administered to the subject both topically and orally, in combination. In an particularly preferred embodiments, the folate is leucovorin, folic acid, or a combination of these two folates.
Broadly speaking, the invention also provides compositions for reducing UV damage to cells, comprising vitamin B12, niacinamide and at least one folate, and a suitable carrier. In one preferred embodiment, folate is present in the composition at a concentration in the range of approximately 0.1 to 3mg/ml and, the carrier is suitable for topical application. Niacinamide is present at approximately 100X this amount ie 1.0 to 30mg/ml. Vitamin B12 is present in the range 0.1 mg to limits of its solubility. In another preferred embodiment, a folate is present in the composition in a total dosage of up to 10.0 mg, niacinamide in an amount up to 1000 mg, vitamin B12 up to 1.5 mg and the carrier is suitable for oral administration. In a particularly preferred embodiment, the folate is leucovorin, folic acid, or a combination of these two folates or their pharmaceutically-acceptable salts.
The claimed invention has the advantage that administration of the vitamin mixture containing vitamin 812, a folate, and niacinamide, for the purposes of reducing UV damage to the cells of a subject can be done either topically, systemically (orally or by injection), or via a combination of routes.
Systemic delivery of the vitamin mixture might afford protection to the eye, something that cannot readily be accomplished by commercially available topical sunscreens. Such a treatment might be expected to lessen the risk of cataracts induced by UV light. Secondly, protection from UV light by a naturally occurring compound may avoid exposure to chemicals that may be toxic, genotoxic (mutagenic or carcinogenic) or irritating to the subject. Thirdly, the invention provides a method to filter or absorb harmful UV rays through the use of bioavailable compounds. Bioavailable compounds are chemicals, usually from natural sources, that are readily taken up and metabolized by cells. Because these compounds are simple B complex vitamins with other known effects their ingestion or topical application may have other health benefits than those described herein. Other features and advantages of the invention will be evident from the following description and the claims.
DETAILED DESCRIPTION OF THE INVENTION
Vitamin B12 f=olates A number of folates, described below, are applicable to the invention. For the purposes of this patent application, the term "folate" or "folates" mean folic acid, its precursors, its metabolites, its derivatives, including polygutamated derivatives, its conjugates, as well as the salts of the foregoing compounds, all of which may be naturally occurring or synthetic. "Reduced folates" means folates at the dihydro and tetrahydro level of oxidation, for example folinic acid or folinate. The folates referred to above include, but are not limited to, the following: folic acid, dihydrofolic acid, tetrahydrofolic acid, 5-formyltetrahydrofolic acid (folinic acid, leucovorin), 10-formyltetrahydrofolic acid, 5-10 methylenetetrahydrofolic acid, 5-10 methenyltetrahydrofolic acid and 5-methyltetrahydrofolic acid. Of these, folic acid and folinic acid and their salts are preferred.
Folic acid is formed from three separate chemical building blocks:
~ a heterocyclic pteridine ring, 6-methylpterin ~ p-aminobenzoic acid (pABA), and ~ glutamic acid.
The 6-methylpterin moiety is linked through the amino group on pABA to form pteric acid, which is in tum linked through an amide to glutamate. Pteric acid that is linked to a single glutamate is known as pteroylmonoglutamate.
However, many naturally occurring folates have additional glutamate residues attached to pteric acid (pterylpolyglutamates). The additional glutamate residues, linked by means of a modified peptide bond involving the alpha-amino group of one glutamate and the gamma-carboxyl group of another, allow for compartmentalization of different reduced folates in cells and provide an additional level of regulation for folate interconversion enzymes.
It is believed that only the monoglutamate forms of folate are transported into human cells. Other glutamate groups are added subsequently. One function of these polyglutamated derivatives is to maintain intracellular pools of reduced folates. The term folate, as used herein includes such polyglutamated derivatives.
Humans cannot synthesize folic acid de novo. Inside cells, folic acid is metabolized to dihydrofolate and then to tetrahydrofolate by means of an enzyme known as dihydrofolate reductase (DHFR). Tetrahydrofolate is converted to a variety of reduced intermediates involved in the mobilization and utilization of single-carbon functional groups (i.e. methyl, methenyl, methylene and formyl).
These one carbon donors function in the metabolism of certain amino acids such as serine, glycine, methionine, and histidine, and in the biosynthesis of purine and pyrimidine nucleotides. In the latter pathway a reduced folate donates the methyl group of thymine via thymidylate synthase without which cells lack one of the basic building blocks of DNA synthesis. Consequently, depletion of reduced folates (usually due to DHFR inhibition) is lethal to cells. The effects of partial folate starvation on cells is not known but it is reasonable to suppose that they are impaired in nucleotide synthesis and thus cannot synthesize and repair DNA
at normal rates.
Pathways for the biosynthesis, interconversion, and utilization of a number of naturally occurring folates in human cells are illustrated in Figure 1.
Many folates exist in nature, but they can also be manufactured by chemical synthesis. For purposes of this application, the term folate encompasses both naturally occurring and synthetic forms.
Folates can be used as a single chemical species or a mixture of two or more species. It is anticipated that a mixture of folates may be more effective than a single species. For example, the UV absorption spectra of folic acid and folinic acid cover a broader spectrum of absorption than either compound alone.
Some of the folates of the invention can be obtained commercially from a number of sources. Folic acid, folinic acid and 5-methyltetrahydrofolate acid are available from Sigma Chemical Co., St Louis Mo. Other folates that are not commercially available can be prepared by a chemist of ordinary skill in the art, (see U.S. patent no. 5,410,056, which is hereby incorporated by reference in its entirety) Conjugates of the folates such as those with amino acid side chains can be prepared by published methods (see Ayling, J. and Baugh, N., Chemistry and Biology of Pteridines and Folates, 1993, Plenum Press NY, which is hereby incorporated by reference in its entirety).
The folates of the invention need not be highly purified. Mixtures of partially purified folates can be used. Folates or combinations of folates can be tested for their ability to protect cells from UV light, by using the a screen such as the human fibroblast cell culture system described herein. The folates to be tested would be added to cultures of mammalian cells before, during or after exposure to UV light. Folates that are effective blocks to UV light would increase cell survival.
Administration of the B Vitamin Formulation The methods of the invention are applicable to cells of any organism that can potentially be damaged by UV light. For the purposes of this patent application, the term "subject" means a whole multi-cellular organism, which includes humans, lower animals and plants. In a preferred embodiment, the methods and compositions are applied to human cells, particularly human cells which are subject to sun exposure, such as melanocytes, and the squamous and basal cells of the dermis and epidermis.
For cells that are maintained in tissue culture, the vitamins are administered by adding them to the growth medium in which the cells are maintained.
For whole organisms, including humans, the compounds may be administered topically, by applying them to the outside skin or surface of the organism. Without being bound by any theory, it is suggested that the folates used in the invention act both extracellularly and intracellularly. Many types of cells are permeable to at least some of the folates that are used to carry out the invention. For example, mouse L1210 cells, can take up folates such as 5-methyltetrahydrofolate, by at least two mechanisms; a specific transporter in the cell membrane that operates in the micromolar range and a second transport system that takes up folates in the nanomolar range.
A lack of permeability to a particular folate does not necessarily exclude the compound from intracellular use. Various methods can be used to facilitate the entry of the folates into cells. For example, the liposome-mediated methods, which have been developed for the delivery of DNA repair enzymes, as mentioned above, can be adapted to deliver the three B complex vitamins into cells. Such methods are disclosed in US Patent Numbers 5,077,211 and 5,352,458, which are hereby incorporated by reference in their entirety.
For purposes of administration of the three B vitamins alone or in combination to a subject, they are incorporated into a pharmaceutically acceptable carrier, which can take many different forms. By "pharmaceutically-acceptable" is meant that the carrier comprises common pharmaceutical and cosmetic ingredients that are generally recognized as safe for human use. A
suitable topical carrier can be in the form of a water-in-oil emulsion, These emulsions can be thin or thick in consistency, so as to be adaptable to spray or aerosol delivery, lotions, creams, etc. Some folates are water-soluble, and can be used without an oil component in the carrier.
If it is desired to deliver the three B vitamins into cells, oral or paranteral routes can be used.
Methods and compositions for administration via oral and parenteral routes are well know in the art. (For example, see Ansel, A. C., Popovich, N.G., and Allen Jr., L.V. Pharmaceutical Dosage Forms and Drua Deliver)i Systems, 6th Edition. 1995. Williams & Wilkings, Baltimore, which is hereby incorporated by reference in its entirety.) Topical application to the epidermis of a subject can also be an effective route to deliver bioavailable folates, niacinamide and vitamin B12.
Many appropriate carriers for topical administration are described in the above-noted reference by Ansel et al., including ointments, creams, sprays and lotions. Other appropriate carriers are disclosed in the following patents, hereby incorporated by reference: US 4,401,664, US 4,938,969, US 5,607,622, and US
5,153,230.
The B complex vitamin formulation could also be administered via microsponge delivery system, as described in K. Embil and S. Nacht, 1996, "The microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives" J
Microencapsul 13: 575-588.
Although topical or oral delivery would seem the most practical, for some human subjects who are extremely light sensitive due to treatment with various prescription medicines( eg tetracycline) or who are afflicted with certain medical conditions ( eg burn patients) or genetic disorders ( eg xeroderma pigmentosum), it is conceivably advantageous to deliver the composition systemically by means of intravenous, subcutaneous or intra-muscular routes.
The compositions used in the invention may contain additional ingredients in addition to folates and suitable carriers. The compositions may also contain various agents whose purpose is mainly cosmetic or esthetic, such as perfuming agents, colorants, etc. The composition may also contain other compounds used as sunblocks, or to prevent photoaging of human skin. These include but are not restricted to: cinnamate, benzophenone, beta-carotene, and alpha-hydroxy acids. In particular, Vitamin E (alpha-tocopherol), often used in commercial skin care products could be incorporated into the composition.
The composition may also contain agents that promote absorption into the skin, for example, propylene glycol, which was used in Example 1 and 2. The folate compounds of the invention could also be administered in liposomes, or liposomes that also contain DNA repair enzymes, as outlined in US Patent Numbers 5,077,211 and 5,352,458.
The appropriate concentration of folates in the composition to be administered to a subject varies depending on the particular folate, the route of administration, and the cells to which it is targeted. However, for intracellular effects, the concentration of folates should be tailored to result in the accumulation in the cells of sufficient concentrations of the three B complex vitamins to reduce UVR damage to the cells. For UV absorption or blocking on the outer surfaces of the subject, the concentration of vitamins should be adjusted to result in the desired degree of absorption or blocking.
Preferably, the concentration of folates in the composition is between (0.002 and 10 mg/ml), and more preferably between (0.002 mg/ml and the limits of solubility of the folate compound in any particular carrier). The concentration of niacinamide will be 100 times this amount. The vitamin B12 concentration will be in the range 0.1 mg/ml to the limits of solubility of the vitamin. The topical composition can be reapplied periodically during sun exposure to replace removed or absorbed material.
If the three B complex vitamins are administered orally, the composition, in a suitable carrier, can be administered daily or several times during the day.
The composition could be administered in a pill or capsule, orally or sub-lingually or in the form of a juice or other suitable drink. A daily dosage of folates in the range of 0.02 mg/kg to 0.05mg/kg, and preferably between 0.02 mg/kg and 0.2 mg/kg, and more preferably between 0.02mg/kg and 1 mg/kg can be ingested orally. The amount of niacinamide will be 100 times this amount. Vitamin B12 can be ingested in the range 0.001 mg/kg to 1 mg/kg.
The effective amount of a particular B complex vitamin can readily be determined by a person skilled in the art by a variety of common assay systems.
Drawings: none Experimental Evidence:
B COMPLEX VITAMIN COMPOSITIONS THAT PROTECT AGAINST
CELLULAR DAMAGE CAUSED BY ULTRAVIOLET LIGHT
FIELD OF THE INVENTION
The invention relates generally to sunscreens and sunfilters, and to methods and compositions for protecting cells against the damaging effects of sunlight and artificial sources of UV light such as lamps and arc welding equipment.. In particular, the invention is directed to the use of vitamin B12, alone or in combination with folate (used here to refer to the family of folic acid derivatives found commonly in nature), and niacin (specifically niacinamide) in methods and compositions for protecting cells and organisms including humans against the burning, genotoxic, immunosuppressive and photoaging effects of UV
light.
BACKGROUND OF THE INVENTION
Over the past several decades, the worldwide incidence of skin cancer has been increasing at an alarming rate. The reason for this dramatic increase in skin cancers and the human suffering associated with these disorders is not entirely clear, but many experts believe that it is due, at least in part, to depletion of the earth's protective ozone layer. It is likely that the widespread use of sunscreens that protect against some but not all of the sun's harmful UV
radiation (UVB but not UVA) also has played a role. According to the National Cancer Institute (NCI), there will be over one million new cases of skin cancer reported in the United States this year. This nears the total of all other cancers combined. NCI also reported that if present trends continue 40-50% of fair skinned Americans are expected to develop at least one type of skin cancer by age sixty-five. These numbers are alarming, but in regions of the world closer to the equator, the rates of skin cancer are even higher.
In some regions of Australia for example, the probability of non-indigenous people (most of whom are of European descent) developing skin cancer at some point during their lifetime approaches 100%. Skin cancers are now the main cause of death in Australia of all persons between the ages of 25 and 40. Worldwide, skin cancer is expected to become the leading cause of death due to malignant disease in the next decade.
How did this alarming situation come about? It is likely that the worldwide pandemic of skin cancers is due to a number of causal factors. These include lifestyle choices (suntanning, increased outdoor leisure activities), an aging population (due to chronic sun exposure and decreased DNA repair capacity) dietary factors (folic acid is the most common nutritional deficiency in the world and other micro-nutrient deficiencies) and environmental factors (workplace hazards and depletion of the ozone layer). In addition to increased risk of skin cancer, exposure to sunlight has a variety of adverse effects on the human body including erythema (burning of the skin), photoaging (wrinkling) and suppression of the immune system. Recently it has also been suggested that sunlight exposure in women might also increase the risk of neural tube defects in _2_ the developing fetus (ref) and risk of developing endometriosis (a condition characterized by invasion of the inner lining (endometrium) tissue into the outer layers of the uterus.) For many years it was thought by most scientific investigators that these various effects were quite separate consequences of sunlight exposure.
However, recent evidence has suggested that many of the effects of solar light on the human body might be interrelated. For example, children who experience only a single episode of blistering sunburn in childhood (before the age of 18) double their risk of developing skin cancer later in life. Tanning of the skin, long thought to be an important component of a healthy lifestyle is now considered by most experts to be quite the opposite and should be more properly considered as simply the unhealthy appearance of sundamaged skin. In addition, contrary to another widely held belief, it is now well documented that tanning confers no protection whatsoever against the most serious effect of chronic sun exposure, the increased risk of skin cancer.
The skin cancers induced by sunlight can be broadly categorized into two types: melanomas and non-melanomas (basal-cell and squamous). It was generally accepted for some time that exposure to UVB (the burning rays of the sun with the wavelengths ranging from 280 to 315 nm) was responsible for the induction of melanomas, the most serious form of skin cancer and the tumor type responsible for most deaths. This was held to be especially true in those individuals who had at least one episode of severe sunburn early in childhood.
It seems likely from more recent studies, (especially an elegant series of experiments by Dr Richard Setlow reported recently to the American Academy of Dermatology that this is simply not the case. Based on spectral and mutational fingerprint analysis (each type of UV light causes a characteristic mutational pattern in target genes) Dr Setlow suggests that melanomas are due mainly to chronic exposure to UVA, wrongly considered by many people to be the harmless tanning rays of the sun, UVA has wavelengths between 320 and 400 nm. UVA has less energy than UVB but is more penetrating and passes through window glass and into deeper layers of the skin more easily.
Recent experimental evidence suggests UVB induces mainly non-melanoma skin cancers.
There are several implications of this new understanding of the carcinogenic potential of UVA and UVB. First, UVA light passes easily through the atmosphere and is not absorbed by the ozone layer. It is the main type of solar UV irradiation (about 95%) that reaches the surface of the earth. In the past, it was generally believed that UVA had only beneficial effects to humans such as stimulation of vitamin D formation and tanning. However, this is clearly not the case. Wavelengths in the UVA range induce melanomas. Second depletion of the ozone layer which permits passage of more UVB light cannot be the explanation for the dramatic increase in melanomas seen worldwide in recent years. More likely it is due to the widespread use of sunscreen products that slow burning of the skin by filtering UVB and give a false impression to the user that sundamage is not occurring. These individuals are not only at greater risk of melanoma formation but also increased risk of photoaging of the skin suppression of their immune system. Lastly, chronic exposure to UVA over the lifetime of an individual and not acute sunburn in childhood is now considered to be responsible for the majority of melanomas, the most serious form of skin cancer and the type causing most deaths (six out of seven deaths due to skin cancer in the United States are caused by melanomas). The general implication of these findings is that tanning is unhealthy whether done in sunlight or by exposure to artificial sources of UVA such as those used in salons. It is now recommended by the US FDA that people avoid tanning salons altogether and that sunscreen products should contain both UVA and UVB filters.
The mechanism of UV damage to skin is only partly understood. The harmful effects of UVA and UVB light on human skin are due primarily to direct cellular damage (see Princiales and Practice of Dermatology, 2nd Edition, Williams and Wilkins, Churchill/Livingston, N.Y.). Suppression of the immune system also occurs but by an indirect mechanism. The genotoxic potential of solar light resides mainly in the ability of UV to damage DNA (DNA absorbs maximally at 254nm). UV light causes the formation of various photoproducts in the strands of the DNA molecule. The major photoproducts caused by UV light are dimers (fusions) of adjacent pyrimidines (thymine or cytosine residues) in one of the two strands of the DNA molecule. Other minor products like 6,4 photoproducts also occur. But DNA is not the only target of UV light. UV also damages other cellular components such as collagen. This causes photoaging of the skin. But the main genotoxic (mutagenic and carcinogenic) effects of UV
light seems to reside in the ability of UV wavelengths to damage DNA. The cancer causing effects of UV light are can also reside in the ability of these wavelengths to impair the body's immunosurveillance system whose job it is to detect and destroy potentially malignant cells. In the absence of a properly functioning immunosurveillance system, skin cancers arising from cells harboring tumorigenic mutations caused by sunlight are more likely.
In the art numerous screening and ~Itering agents have been developed over many years, to protect skin against the deleterious affects of UV light.
These agents are applied directly to the skin of a subject, and are believed to prevent UV light from penetrating the epidermis by acting as "filters,"
thereby absorbing or otherwise dissipating the energy contained in photons of UV
light.
Previously it was widely accepted in the industry that agents called "sunblocks"
decreased UV-induced DNA damage, and in particular, pyrimidine dimer formation by UV opaque substances. In support of this view a recent clinical study indicated that "sunblocks" such as titanium oxide significantly reduced the incidence of pre-cancerous skin lesions in sunlight-exposed subjects. However, the term "sunblock" is no longer accepted by the US Food and Drug Agency (FDA). The FDA believes the term is misleading as no agent truly "blocks" all harmful UV rays and implies a greater degree of protection from the damaging effects of sunlight than is warranted.
Para-aminobenzoic acid (pABA), was one of the first sunfiltering agents to be identified in the art. It is now seldom used because of problems with contact dermatitis. Due to widespread use of pABA over many years about 10% of all users of sunscreen products have some degree of contact sensitivity to the compound. However, esters of pABA, particularly octyl, dimethyl, para-aminobenzoic acid, do not elicit these same skin reactions. Other commonly used sunfilters are compounds from the salicyclate, cinnamate, benzophenone, anthranilate, and dibenzoylmethane families of molecules. It is well known in the art to combine sunfiltering agents that absorb UV light in different portions of the spectrum. However, most of these agents are synthetic chemicals not found in commonly in nature and it is not known what effects longterm use of these compounds may have on the human body.
Sunscreen compositions exert their effects through filtering or absorbing UV light so that the damaging wavelengths do not penetrate the various layers of the skin. To be effective, sunscreens must be present on the skin as a continuous film, and must remain on the surface of the skin throughout the period of UV exposure. One of the problems with products currently in use is that despite numerous attempts to develop topical compositions that act as sunscreen carriers and remain on the surface of the skin (see U.S. Patent No.
5,087,445), sunscreens tend to rub off on towels and clothing, and wash off in perspiration, or during swimming, showering and bathing. Even if carriers are developed that remain on the surface of the skin for longer periods absorption of sunscreen (and cosmetic) additives into the skin remains a problem. This is due to the surprising fact that many sunfiltering agents used as sunscreen and cosmetic additives themselves cause DNA damage. Titanium dioxide for example a very common additive has long been considered to be safe and effective as a sunscreening agent. This may not be the case (see Salinaro et al., 1997, "Chemical oxidation and DNA damage catalysed by inorganic sunscreen ingredients" FEES Lett 418:87-90). Padimate-O, another common sunscreen additive in widespread use may also be genotoxic ( see P.J. McHugh and J.
Knowland, 1997, "Characterization of DNA damage inflicted by free radicals from a mutagenic sunscreen ingredient and its location using an in vitro genetic reversion assay" Photochem Photbiol 66:276-281.]
A recent research article (G.J. Cameron et al., 1997, "Systemic absorption of sunscreen after topical application" The Lancet 350: 863-864) has shown that the UVA sunscreen oxybenzone, a benzophenone derivative used commonly worldwide to make sunscreen products with high sun protection factors (SPF) is absorbed systemically and excreted in human urine soon after application to the skin. The repeated use of a sunscreen that is absorbed systemically could pose an especially high risk to human health if the sunscreen agent is chronically genotoxic. A recent and alarming finding is that at low concentration most if not all of the sunscreen agents currently in use are both mutagenic and tumorigenic (R C von Borstel, personal communication). The tumor incidence was very high in along the borders of applied sunscreen in experimental animals.
These findings have added a new urgency to the development of novel sunfiltering agents that are not only effective in reducing the harmful effects of UV light, but are also safe, even upon repeated usage and over a long period of time. Subsequent to experiments on the role of the vitamin folic acid in the repair of UV damage to DNA ( see Barclay et al exp med boil 1993) my collaborators and I discovered what we believe might be a natural sunfilter in the human body.
-8_ The compound is a folate which occurs naturally in the bloodstream and is also associated with hemoglobin in red blood cells.
SUMMARY OF THE INVENTION
The object of the invention is to provide a means of reducing the burning, genotoxic, immunosuppressive and photoaging effects of UV light by application of three common B vitamins to the skin The term "vitamin B12", "folate" and "niacinamide" as used herein, includes the parent compounds, their precursors (pro-vitamins), metabolites, derivatives, and their conjugates, all of which may be either naturally occurring or synthetic, as well as the salts of the compounds. Results of experiments with human volunteers described below have shown that the combination folic acid, vitamin B12 and niacinamide when taken in pill form prevented sunburning for many hours. It is assumed that topical application would be effective in a similar fashion.
Broadly speaking, the invention provides a method for reducing UV
damage to cells, comprising exposing the cells to an amount of at least one of vitamin B12 or folate but preferably the two vitamins in combination with niacinamide, in appropriate concentration, which is sufficient to reduce UV
damage to cells, specifically skin cells. In one embodiment, the invention is a method for reducing UV damage to the outer cell layers of a subject, comprising administering to the subject a formulation of vitamin B12, folate and niacinamide, in a suitable carrier, the amounts of each individual component sufficient to _g_ reduce UV damage to cells. In one preferred embodiment, the carrier is suitable for topical application, and the composition is applied to the skin of the subject.
In another preferred embodiment, the carrier is suitable for oral administration, and the composition is ingested by the subject. In another preferred embodiment, the three B vitamins, in suitable carriers, are administered to the subject both topically and orally, in combination. In an particularly preferred embodiments, the folate is leucovorin, folic acid, or a combination of these two folates.
Broadly speaking, the invention also provides compositions for reducing UV damage to cells, comprising vitamin B12, niacinamide and at least one folate, and a suitable carrier. In one preferred embodiment, folate is present in the composition at a concentration in the range of approximately 0.1 to 3mg/ml and, the carrier is suitable for topical application. Niacinamide is present at approximately 100X this amount ie 1.0 to 30mg/ml. Vitamin B12 is present in the range 0.1 mg to limits of its solubility. In another preferred embodiment, a folate is present in the composition in a total dosage of up to 10.0 mg, niacinamide in an amount up to 1000 mg, vitamin B12 up to 1.5 mg and the carrier is suitable for oral administration. In a particularly preferred embodiment, the folate is leucovorin, folic acid, or a combination of these two folates or their pharmaceutically-acceptable salts.
The claimed invention has the advantage that administration of the vitamin mixture containing vitamin 812, a folate, and niacinamide, for the purposes of reducing UV damage to the cells of a subject can be done either topically, systemically (orally or by injection), or via a combination of routes.
Systemic delivery of the vitamin mixture might afford protection to the eye, something that cannot readily be accomplished by commercially available topical sunscreens. Such a treatment might be expected to lessen the risk of cataracts induced by UV light. Secondly, protection from UV light by a naturally occurring compound may avoid exposure to chemicals that may be toxic, genotoxic (mutagenic or carcinogenic) or irritating to the subject. Thirdly, the invention provides a method to filter or absorb harmful UV rays through the use of bioavailable compounds. Bioavailable compounds are chemicals, usually from natural sources, that are readily taken up and metabolized by cells. Because these compounds are simple B complex vitamins with other known effects their ingestion or topical application may have other health benefits than those described herein. Other features and advantages of the invention will be evident from the following description and the claims.
DETAILED DESCRIPTION OF THE INVENTION
Vitamin B12 f=olates A number of folates, described below, are applicable to the invention. For the purposes of this patent application, the term "folate" or "folates" mean folic acid, its precursors, its metabolites, its derivatives, including polygutamated derivatives, its conjugates, as well as the salts of the foregoing compounds, all of which may be naturally occurring or synthetic. "Reduced folates" means folates at the dihydro and tetrahydro level of oxidation, for example folinic acid or folinate. The folates referred to above include, but are not limited to, the following: folic acid, dihydrofolic acid, tetrahydrofolic acid, 5-formyltetrahydrofolic acid (folinic acid, leucovorin), 10-formyltetrahydrofolic acid, 5-10 methylenetetrahydrofolic acid, 5-10 methenyltetrahydrofolic acid and 5-methyltetrahydrofolic acid. Of these, folic acid and folinic acid and their salts are preferred.
Folic acid is formed from three separate chemical building blocks:
~ a heterocyclic pteridine ring, 6-methylpterin ~ p-aminobenzoic acid (pABA), and ~ glutamic acid.
The 6-methylpterin moiety is linked through the amino group on pABA to form pteric acid, which is in tum linked through an amide to glutamate. Pteric acid that is linked to a single glutamate is known as pteroylmonoglutamate.
However, many naturally occurring folates have additional glutamate residues attached to pteric acid (pterylpolyglutamates). The additional glutamate residues, linked by means of a modified peptide bond involving the alpha-amino group of one glutamate and the gamma-carboxyl group of another, allow for compartmentalization of different reduced folates in cells and provide an additional level of regulation for folate interconversion enzymes.
It is believed that only the monoglutamate forms of folate are transported into human cells. Other glutamate groups are added subsequently. One function of these polyglutamated derivatives is to maintain intracellular pools of reduced folates. The term folate, as used herein includes such polyglutamated derivatives.
Humans cannot synthesize folic acid de novo. Inside cells, folic acid is metabolized to dihydrofolate and then to tetrahydrofolate by means of an enzyme known as dihydrofolate reductase (DHFR). Tetrahydrofolate is converted to a variety of reduced intermediates involved in the mobilization and utilization of single-carbon functional groups (i.e. methyl, methenyl, methylene and formyl).
These one carbon donors function in the metabolism of certain amino acids such as serine, glycine, methionine, and histidine, and in the biosynthesis of purine and pyrimidine nucleotides. In the latter pathway a reduced folate donates the methyl group of thymine via thymidylate synthase without which cells lack one of the basic building blocks of DNA synthesis. Consequently, depletion of reduced folates (usually due to DHFR inhibition) is lethal to cells. The effects of partial folate starvation on cells is not known but it is reasonable to suppose that they are impaired in nucleotide synthesis and thus cannot synthesize and repair DNA
at normal rates.
Pathways for the biosynthesis, interconversion, and utilization of a number of naturally occurring folates in human cells are illustrated in Figure 1.
Many folates exist in nature, but they can also be manufactured by chemical synthesis. For purposes of this application, the term folate encompasses both naturally occurring and synthetic forms.
Folates can be used as a single chemical species or a mixture of two or more species. It is anticipated that a mixture of folates may be more effective than a single species. For example, the UV absorption spectra of folic acid and folinic acid cover a broader spectrum of absorption than either compound alone.
Some of the folates of the invention can be obtained commercially from a number of sources. Folic acid, folinic acid and 5-methyltetrahydrofolate acid are available from Sigma Chemical Co., St Louis Mo. Other folates that are not commercially available can be prepared by a chemist of ordinary skill in the art, (see U.S. patent no. 5,410,056, which is hereby incorporated by reference in its entirety) Conjugates of the folates such as those with amino acid side chains can be prepared by published methods (see Ayling, J. and Baugh, N., Chemistry and Biology of Pteridines and Folates, 1993, Plenum Press NY, which is hereby incorporated by reference in its entirety).
The folates of the invention need not be highly purified. Mixtures of partially purified folates can be used. Folates or combinations of folates can be tested for their ability to protect cells from UV light, by using the a screen such as the human fibroblast cell culture system described herein. The folates to be tested would be added to cultures of mammalian cells before, during or after exposure to UV light. Folates that are effective blocks to UV light would increase cell survival.
Administration of the B Vitamin Formulation The methods of the invention are applicable to cells of any organism that can potentially be damaged by UV light. For the purposes of this patent application, the term "subject" means a whole multi-cellular organism, which includes humans, lower animals and plants. In a preferred embodiment, the methods and compositions are applied to human cells, particularly human cells which are subject to sun exposure, such as melanocytes, and the squamous and basal cells of the dermis and epidermis.
For cells that are maintained in tissue culture, the vitamins are administered by adding them to the growth medium in which the cells are maintained.
For whole organisms, including humans, the compounds may be administered topically, by applying them to the outside skin or surface of the organism. Without being bound by any theory, it is suggested that the folates used in the invention act both extracellularly and intracellularly. Many types of cells are permeable to at least some of the folates that are used to carry out the invention. For example, mouse L1210 cells, can take up folates such as 5-methyltetrahydrofolate, by at least two mechanisms; a specific transporter in the cell membrane that operates in the micromolar range and a second transport system that takes up folates in the nanomolar range.
A lack of permeability to a particular folate does not necessarily exclude the compound from intracellular use. Various methods can be used to facilitate the entry of the folates into cells. For example, the liposome-mediated methods, which have been developed for the delivery of DNA repair enzymes, as mentioned above, can be adapted to deliver the three B complex vitamins into cells. Such methods are disclosed in US Patent Numbers 5,077,211 and 5,352,458, which are hereby incorporated by reference in their entirety.
For purposes of administration of the three B vitamins alone or in combination to a subject, they are incorporated into a pharmaceutically acceptable carrier, which can take many different forms. By "pharmaceutically-acceptable" is meant that the carrier comprises common pharmaceutical and cosmetic ingredients that are generally recognized as safe for human use. A
suitable topical carrier can be in the form of a water-in-oil emulsion, These emulsions can be thin or thick in consistency, so as to be adaptable to spray or aerosol delivery, lotions, creams, etc. Some folates are water-soluble, and can be used without an oil component in the carrier.
If it is desired to deliver the three B vitamins into cells, oral or paranteral routes can be used.
Methods and compositions for administration via oral and parenteral routes are well know in the art. (For example, see Ansel, A. C., Popovich, N.G., and Allen Jr., L.V. Pharmaceutical Dosage Forms and Drua Deliver)i Systems, 6th Edition. 1995. Williams & Wilkings, Baltimore, which is hereby incorporated by reference in its entirety.) Topical application to the epidermis of a subject can also be an effective route to deliver bioavailable folates, niacinamide and vitamin B12.
Many appropriate carriers for topical administration are described in the above-noted reference by Ansel et al., including ointments, creams, sprays and lotions. Other appropriate carriers are disclosed in the following patents, hereby incorporated by reference: US 4,401,664, US 4,938,969, US 5,607,622, and US
5,153,230.
The B complex vitamin formulation could also be administered via microsponge delivery system, as described in K. Embil and S. Nacht, 1996, "The microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives" J
Microencapsul 13: 575-588.
Although topical or oral delivery would seem the most practical, for some human subjects who are extremely light sensitive due to treatment with various prescription medicines( eg tetracycline) or who are afflicted with certain medical conditions ( eg burn patients) or genetic disorders ( eg xeroderma pigmentosum), it is conceivably advantageous to deliver the composition systemically by means of intravenous, subcutaneous or intra-muscular routes.
The compositions used in the invention may contain additional ingredients in addition to folates and suitable carriers. The compositions may also contain various agents whose purpose is mainly cosmetic or esthetic, such as perfuming agents, colorants, etc. The composition may also contain other compounds used as sunblocks, or to prevent photoaging of human skin. These include but are not restricted to: cinnamate, benzophenone, beta-carotene, and alpha-hydroxy acids. In particular, Vitamin E (alpha-tocopherol), often used in commercial skin care products could be incorporated into the composition.
The composition may also contain agents that promote absorption into the skin, for example, propylene glycol, which was used in Example 1 and 2. The folate compounds of the invention could also be administered in liposomes, or liposomes that also contain DNA repair enzymes, as outlined in US Patent Numbers 5,077,211 and 5,352,458.
The appropriate concentration of folates in the composition to be administered to a subject varies depending on the particular folate, the route of administration, and the cells to which it is targeted. However, for intracellular effects, the concentration of folates should be tailored to result in the accumulation in the cells of sufficient concentrations of the three B complex vitamins to reduce UVR damage to the cells. For UV absorption or blocking on the outer surfaces of the subject, the concentration of vitamins should be adjusted to result in the desired degree of absorption or blocking.
Preferably, the concentration of folates in the composition is between (0.002 and 10 mg/ml), and more preferably between (0.002 mg/ml and the limits of solubility of the folate compound in any particular carrier). The concentration of niacinamide will be 100 times this amount. The vitamin B12 concentration will be in the range 0.1 mg/ml to the limits of solubility of the vitamin. The topical composition can be reapplied periodically during sun exposure to replace removed or absorbed material.
If the three B complex vitamins are administered orally, the composition, in a suitable carrier, can be administered daily or several times during the day.
The composition could be administered in a pill or capsule, orally or sub-lingually or in the form of a juice or other suitable drink. A daily dosage of folates in the range of 0.02 mg/kg to 0.05mg/kg, and preferably between 0.02 mg/kg and 0.2 mg/kg, and more preferably between 0.02mg/kg and 1 mg/kg can be ingested orally. The amount of niacinamide will be 100 times this amount. Vitamin B12 can be ingested in the range 0.001 mg/kg to 1 mg/kg.
The effective amount of a particular B complex vitamin can readily be determined by a person skilled in the art by a variety of common assay systems.
Drawings: none Experimental Evidence:
Claims (20)
1. A method for reducing the damaging effects of ultraviolet radiation to cells of a subject comprising exposing the cells to an effective amount of a composition containing vitamin B12.
2. The method of Claim 1 wherein the composition is taken orally
3. The method of Claim 1 wherein the composition is applied to the skin.
4. The method of Claim 1 wherein the composition is taken by injection.
5. The method of Claim 1 wherein the composition in addition to vitamin B12 also comprises at least one anti-photoaging compound.
6. The method of Claim 1 wherein the composition comprises in addition to vitamin B12 at least one sunfiltering or suncreening compound including other vitamins.
7. The method of Claim 1, wherein the subject is an animal.
8. The method of Claim 1 wherein the animal is a human.
9. The method of Claim 1 wherein the composition is incorporated into a liposome.
10. The method of Claim 1 wherein the composition also comprises at least one DNA repair enzyme.
11. The method of Claim 2 wherein the amount of vitamin B12 ingested is between 0.1 mg and 1.5 mg.
12. The method of Claim 2 wherein the composition also contains any folate in the range 1 mg to 10 mg.
13. The method of Claim 2 wherein the composition also contains niacin or any derivative of niacin in the range 100 mg to 1 g.
14. The method of Claim 1 wherein the composition is applied to the to the skin of the subject in a continuous film.
15. The method of Claim 14 wherein the composition comprises vitamin B12 at a concentration of between 0.1 mg/ml and 10 mg/ml in a pharmaceutically-acceptable carrier.
16. The method of claim 14 wherein the composition comprises in addition to vitamin B12 any folate at a concentration of between 0.2 mg/ml and the upper limit of solubility of the compound in a pharmaceutically-acceptable carrier.
17. The method of claim 14 wherein the composition comprises in addition to vitamin B12, niacinamide or any derivative of niacin in the concentration range 2 mg/ml and the upper limit of solubility of the compound, in a pharmaceutically acceptable carrier.
18. The method of Claim 4 wherein the composition comprises vitamin B12 in an amount between 0.1 mg and 1.5 mg.
19. The method of Claim 4 wherein the composition contains, in addition to vitamin B12, any folate in the range 1 mg to 10 mg.
20. The method of Claim 4 wherein the composition contains, in addition to vitamin B12, niacinamide or any derivative of niacin, in the range100 mg to 1 g.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002313659A CA2313659A1 (en) | 2000-07-06 | 2000-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
PCT/CA2001/001006 WO2002003942A2 (en) | 2000-07-06 | 2001-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
EP01951290A EP1299078A2 (en) | 2000-07-06 | 2001-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
AU2001272274A AU2001272274B2 (en) | 2000-07-06 | 2001-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
AU7227401A AU7227401A (en) | 2000-07-06 | 2001-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
US09/900,064 US7018623B2 (en) | 2000-07-06 | 2001-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002313659A CA2313659A1 (en) | 2000-07-06 | 2000-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2313659A1 true CA2313659A1 (en) | 2002-01-06 |
Family
ID=4166676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002313659A Abandoned CA2313659A1 (en) | 2000-07-06 | 2000-07-06 | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
Country Status (5)
Country | Link |
---|---|
US (1) | US7018623B2 (en) |
EP (1) | EP1299078A2 (en) |
AU (2) | AU7227401A (en) |
CA (1) | CA2313659A1 (en) |
WO (1) | WO2002003942A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302090A (en) * | 2018-12-24 | 2019-10-08 | 中健(广州)生物医药研究院有限公司 | Application of the L-5- methyl tetrahydrofolate glucosamine salt in cosmetics |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DE10062401A1 (en) * | 2000-12-14 | 2002-06-20 | Beiersdorf Ag | Use of folic acid and / or derivatives thereof for the preparation of cosmetic or dermatological preparations for the prophylaxis of damage to the skin's own DNA and / or to repair damage already occurred to the skin's own DNA |
DE10130846A1 (en) * | 2001-06-28 | 2003-01-16 | Regeneratio Pharma Ag | Use of corrinoids for use in skin diseases |
CA2476730C (en) * | 2002-02-21 | 2012-07-10 | Lionel Breton | A photoprotective orally administrable composition for skin |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
KR101108439B1 (en) | 2002-10-25 | 2012-01-31 | 포믹스 리미티드 | Cosmetic and pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
WO2004043422A1 (en) * | 2002-11-13 | 2004-05-27 | Unilever Plc | Improved cosmetic composition |
US7575739B2 (en) * | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
JP2005310310A (en) * | 2004-04-23 | 2005-11-04 | Sanyo Electric Co Ltd | Tracking balance adjustment device |
US8075910B2 (en) * | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
CA2611636C (en) * | 2005-06-21 | 2013-12-10 | South Alabama Medical Science Foundation | Methods and compositions containing natural folates for protecting against radiation damage |
US20060292094A1 (en) * | 2005-06-24 | 2006-12-28 | Robert Bell | Composition and method of protection against UV irradiation |
US20070183995A1 (en) * | 2006-02-09 | 2007-08-09 | Conopco, Inc., D/B/A Unilever | Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same |
US20080075798A1 (en) * | 2006-08-30 | 2008-03-27 | Rosemarie Osborne | Personal care compositions comprising pear seed extract |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
GB0715502D0 (en) * | 2007-08-08 | 2007-09-19 | Univ Manchester | Methods |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
WO2010011927A1 (en) | 2008-07-25 | 2010-01-28 | Noventis, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
CN101669888B (en) * | 2009-09-27 | 2010-12-29 | 纪辉 | New application of vitamin B12 in cosmetics |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
WO2011064631A1 (en) | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
DE102010023626A1 (en) * | 2010-06-14 | 2011-12-15 | Thomas Schütz | Use of corrinoids for medical use in coat and skin diseases in small and large animals (warm and cold-blooded), (for example in fish, birds, horses, cattle, camels, dogs, cats, reptiles) |
CN107670044A (en) | 2010-07-22 | 2018-02-09 | 雷文制药有限公司 | Comprising the treatment using magnetic dipole stabilizing solutions or improve disease and strengthen the method for performance |
BR112013024655A2 (en) * | 2011-03-25 | 2016-12-20 | Selecta Biosciences Inc | synthetic nanotransporters for osmotic mediated release |
US20150023897A1 (en) * | 2013-07-22 | 2015-01-22 | The Procter & Gamble Company | Method of protecting skin from oxidative stress |
AU2015229109B2 (en) | 2014-03-14 | 2018-09-27 | Gojo Industries, Inc. | Hand sanitizers with improved aesthetics and skin-conditioning to encourage compliance with hand hygiene guidelines |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
CN113826905B (en) * | 2021-08-04 | 2023-11-10 | 大连医诺生物股份有限公司 | Photosensitive-resistant vitamin K2 microcapsule preparation and preparation method thereof |
EP4201411A1 (en) * | 2021-12-21 | 2023-06-28 | DSM IP Assets B.V. | Novel use of vitamin b12 |
EP4201410A1 (en) * | 2021-12-21 | 2023-06-28 | DSM IP Assets B.V. | Novel use of vitamin b12 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3210669A1 (en) * | 1982-03-23 | 1983-09-29 | Hrvoje Dr. Zagreb Krnjević | Pharmaceutical composition for the treatment of disorders of the skin and mucous membranes and of nail growth |
JPH01135887A (en) * | 1987-11-20 | 1989-05-29 | Lion Corp | Ultraviolet ray absorber composition |
JPH01135886A (en) * | 1987-11-20 | 1989-05-29 | Lion Corp | Ultraviolet ray absorber |
DE3800968A1 (en) * | 1988-01-15 | 1989-07-27 | Asche Karl W | Substance in powder form as pharmaceutical |
US4985443A (en) * | 1989-08-04 | 1991-01-15 | Montes Leopoldo F | Method and composition for treating vitiligo |
CA2151148A1 (en) * | 1992-12-10 | 1994-06-23 | Richard D. Levere | Method for stimulating production of heme oxygenase using vitamin b12 |
US5496827A (en) * | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
DE19509354A1 (en) * | 1994-12-08 | 1996-06-13 | Klett Loch Lore M | Combination preparation for promoting hair growth and possibly skin and nail growth and for preventing or eliminating hair loss |
US6194452B1 (en) * | 1997-11-07 | 2001-02-27 | Howard Murad | Stable pharmaceutical compositions including ascorbic acid and methods of using same |
US6251878B1 (en) * | 1998-07-10 | 2001-06-26 | Board Of Regents, The University Of Texas System | Inhibition of UV-induced immune suppression and interleukin-10 production by cytoprotective tamarind oligosaccharides |
DE29916231U1 (en) * | 1999-09-15 | 2000-02-17 | Renner Jobst | Multivitamin and mineral preparation |
-
2000
- 2000-07-06 CA CA002313659A patent/CA2313659A1/en not_active Abandoned
-
2001
- 2001-07-06 US US09/900,064 patent/US7018623B2/en not_active Expired - Fee Related
- 2001-07-06 WO PCT/CA2001/001006 patent/WO2002003942A2/en not_active Application Discontinuation
- 2001-07-06 AU AU7227401A patent/AU7227401A/en active Pending
- 2001-07-06 EP EP01951290A patent/EP1299078A2/en not_active Ceased
- 2001-07-06 AU AU2001272274A patent/AU2001272274B2/en not_active Ceased
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302090A (en) * | 2018-12-24 | 2019-10-08 | 中健(广州)生物医药研究院有限公司 | Application of the L-5- methyl tetrahydrofolate glucosamine salt in cosmetics |
Also Published As
Publication number | Publication date |
---|---|
WO2002003942A3 (en) | 2002-05-02 |
US20020035087A1 (en) | 2002-03-21 |
WO2002003942A2 (en) | 2002-01-17 |
AU2001272274B2 (en) | 2007-01-18 |
US7018623B2 (en) | 2006-03-28 |
EP1299078A2 (en) | 2003-04-09 |
AU7227401A (en) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2313659A1 (en) | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light | |
AU2001272274A1 (en) | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light | |
Pathak | Sunscreens: topical and systemic approaches for protection of human skin against harmful effects of solar radiation | |
Garland et al. | Rising trends in melanoma an hypothesis concerning sunscreen effectiveness | |
US6433025B1 (en) | Method for retarding and preventing sunburn by UV light | |
US6455032B1 (en) | Composition and method for protecting skin from UV induced immunosuppression and skin damage | |
Garone et al. | A review of common tanning methods | |
Ferguson et al. | A study of cutaneous photosensitivity induced by amiodarone | |
Gilchrest | Actinic injury | |
Epstein | Photomedicine | |
ROELANDTS | Shedding light on sunscreens | |
CN101203221B (en) | Methods and compositions containing natural folates for protecting against radiation damage | |
Srinivas et al. | Photodermatoses in India | |
Pathak | Photoprotection against harmful effects of solar UVB and UVA radiation: an update | |
Lowe et al. | Sunscreens: rationale for use to reduce photodamage and phototoxicity | |
Kaplan | Suntan, sunburn, and sun protection | |
Pathak et al. | Topical and systemic approaches to protection of human skin against harmful effects of solar radiation | |
Schaefer et al. | State of the art sunscreens for prevention of photodermatoses | |
Hornung | Photoprotection | |
Bens | Sunscreens | |
Hayag et al. | A high SPF sunscreen's effects on UVB-induced immunosuppression of DNCB contact hypersensitivity | |
KR101622387B1 (en) | Composition for Promoting Hair Growth Comprising Melatonin with Improved Stability | |
Pustišek et al. | A review of sunscreens and their adverse reactions | |
Epstein | Biological effects of sunlight | |
WO1994005291A1 (en) | Skin cancer treatment compositions containing dimethyl sulphone and oxypurinol or allopurinol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |